T-cell receptor (TCR) T-cell therapy takes a personalized approach to cancer treatment by engineering a patient’s own T cells to recognize and attack cancer cells. Given as a one-time, single infusion, these cell therapies have the potential to improve the treatment experience for some of the most difficult to treat solid tumor cancers.

Navigating The Complexities and Challenges of Solid Tumor Cancers

While chemotherapy, radiation, surgery, and targeted therapies play pivotal roles in combating solid tumor cancers, they are not always effective, leaving patients in need of second-line therapies.i In addition, the side effects can be incredibly painful – sometimes as debilitating as the cancer itself.ii Unlike liquid tumors, where cancer cells are made of single cell types with the same antigen, solid tumors present uniquely difficult challenges due to their complexity. They are made up of diverse cell types with different mutations, expressing a myriad of antigens.iii These drastic variations often limit the success of existing treatment therapies.iv With solid tumors accounting for nearly 90 percent of all cancer, the need for novel treatment options is more important than ever.iii

Exploring TCR T-cell therapy for Solid Tumor Cancers

Adaptimmune, a cell therapy company, has multiple cell therapies in clinical trials for solid tumors, such as synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), ovarian cancer, and head and neck cancers. These investigational therapies are engineered from a patient’s own cells, targeting very specific antigens in the body, and each delivered in a single dose. As exciting as the science is, the company is driven by the potential impact on patients and families.

“At Adaptimmune, our commitment is to design, develop, and deliver cell therapies with the goal of transforming the lives of people with cancer,” said Dennis Williams, Pharm.D., senior vice president of late-stage development at Adaptimmune.

For more information, we invite you to visit https://www.adaptimmune.com.

About Adaptimmune

Adaptimmune is a fully-integrated cell therapy company working to redefine how cancer is treated. With its unique engineered T-cell receptor (TCR) platform, the company is developing personalized medicines designed to target and combat difficult-to-treat solid tumor cancers and to improve the patient’s cancer treatment experience. The safety and efficacy of TCR T-cell therapies have not been established.

i Zhang, T. (2024). Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances. Journal of Controlled Release, 368, 372-296.

ii Clevland Clinic. “Chemotherapy and Radiation Side Effects.” https://my.clevelandclinic.org/health/articles/10257-chemotherapy-side-effects. Accessed June 6, 2024.

iii Weir, K. “Engineering the Immune System to Tackle Solid Tumors.” Penn Medicine. https://www.pennmedicine.org/news/publications-and-special-projects/penn-medicine-magazine/immune-health/engineering-the-immune-system-to-tackle-solid-tumors. Accessed June 5, 2024.

iv Secondino, S. (2023) Clinical Trials of Cellular Therapies in Solid Tumors. Cancers 2023, 15, 3667.

Disclaimer: Sponsored advertising content is written by the advertiser and does not necessarily reflect the views of Cancer Today or the American Association for Cancer Research (AACR). Cancer Today’s editorial staff was not involved in developing or creating the sponsored content. Content on the Cancer Today website is not intended to be a substitute for professional medical advice. For diagnosis or treatment of any medical condition or any questions you may have about a medical condition, please consult your physician or other qualified health care provider. Neither Cancer Today nor the AACR is liable for any loss or damage incurred as a result of reading or following the information or engaging with any of the advertising or sponsored advertising content on the Cancer Today website. The mention of any company, service, product or treatment does not constitute an endorsement by Cancer Today or the AACR.